{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:49:51Z","timestamp":1790412591207,"version":"4.1.0"},"reference-count":151,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Optimized glycemic management is crucial for controlling atherosclerosis and consequent cardiovascular morbidity in patients with diabetes. Due to the continuous glucose burden from glucose-containing peritoneal dialysis (PD) solutions, PD patients with diabetes experience difficulties in glucose level regulation with glucose hypervariability and worsening dyslipidemia. Even in non-diabetic PD patients, glucose-containing PD solutions aggravate insulin resistance and cause overweight. Additionally, glucose degradation products (GDP) from glucose-based PD solutions provoke oxidative stress and complex inflammatory processes, leading to chronic deleterious and fibrotic peritoneal membrane changes. In this narrative review, we searched the literature using PubMed, MEDLINE, and Google Scholar over the last three decades to summarize the most important facts relevant to the presented issues, aiming to inform both endocrinologists and nephrologists in providing the best currently available care for people with diabetes on PD. We not only focus on adequate tailoring of insulin therapy adapted at the time of PD exchange with hypertonic glucose solution., but also emphasize the use of continuous glucose monitoring (CGM) that allows assessment of mean glucose values and time spent in normal, hypo, and hyperglycemia. However, the routine use of CGM in PD patients is limited due to high cost, and hemoglobin A1c (HbA1c) analysis is still recommended as a basic clinical tool for the assessment of glycemic control. Possible choices of antidiabetic drugs were considered given the narrowed choice due to contraindications for metformin and sulfonylurea. The other important therapeutic approach in PD patients with diabetes is using glucose-sparing PD regimens based on icodextrin and amino acid PD solutions with the addition of just one or two bags of low glucose concentration PD solution daily. This glucose-sparing approach not only reduces the glucose load and improves glycoregulation with correction of the lipid profile but also maintains the viability of the peritoneal membrane by reducing the harmful effects of GDPs.<\/jats:p>","DOI":"10.3390\/life15050798","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T06:54:28Z","timestamp":1747724068000},"page":"798","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Glycemic Control in Patients with Diabetes on Peritoneal Dialysis: From Glucose Sparing Approach to Glucose Monitoring"],"prefix":"10.3390","volume":"15","author":[{"given":"Aleksandra","family":"Kezi\u0107","sequence":"first","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr. Suboti\u0107a 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9359-261X","authenticated-orcid":false,"given":"Selena","family":"Gaji\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Ra\u010di\u0107","family":"Ostoji\u0107","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Clinical Hospital Center Zemun, Vukova 9, 11080 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Beki\u0107","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital for Lung Diseases and Tuberculosis, Clinical Hospital Center \u201cDr Dragi\u0161a Mi\u0161ovi\u0107-Dedinje\u201d, Heroja Milana Tepi\u0107a 1, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bonti\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr. Suboti\u0107a 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Pavlovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr. Suboti\u0107a 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5585-9793","authenticated-orcid":false,"given":"Marko","family":"Barali\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr. Suboti\u0107a 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-9123","authenticated-orcid":false,"given":"Ljiljana","family":"Popovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Dr. Suboti\u0107a 8, 11000 Belgrade, Serbia"},{"name":"Center for Diabetes and Lipid Disorders, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Dr. Suboti\u0107a 13, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The Global Epidemiology of Diabetes and Kidney Disease","volume":"25","author":"Koye","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000506634","article-title":"Diabetic Kidney Disease: Challenges, Advances, and Opportunities","volume":"6","author":"Chen","year":"2020","journal-title":"Kidney Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.17219\/acem\/76751","article-title":"Mortality predictor pattern in hemodialysis and peritoneal dialysis in diabetic patients","volume":"28","author":"Klinger","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.kisu.2019.11.001","article-title":"Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes","volume":"10","author":"Okpechi","year":"2020","journal-title":"Kidney Int. Suppl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2215\/CJN.09301209","article-title":"Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: Comparative results of traditional and time-dependent Cox model analyses","volume":"5","author":"Williams","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1159\/000502145","article-title":"Metabolic Syndrome and Mortality in Continuous Ambulatory Peritoneal Dialysis Patients: A 5-Year Prospective Cohort Study","volume":"44","author":"Gu","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.jrn.2013.01.019","article-title":"Systemic and Local Impact of Glucose and Glucose Degradation Products in Peritoneal Dialysis Solution","volume":"23","author":"Kim","year":"2013","journal-title":"J. Ren. Nutr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/sdi.12198","article-title":"Updates on the management of diabetes in dialysis patients","volume":"27","author":"Rhee","year":"2014","journal-title":"Semin. Dial."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.ki.5001910","article-title":"Mortality studies comparing peritoneal dialysis and hemodialysis: What do they tell us?","volume":"103","author":"Vonesh","year":"2006","journal-title":"Kidney Int. Suppl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2215\/CJN.04810512","article-title":"Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: A marginal structural model analysis","volume":"8","author":"Lukowsky","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/089686080702702s33","article-title":"Peritoneal dialysis in patients with diabetes: Are the benefits greater than the disadvantages?","volume":"27","author":"Kuriyama","year":"2007","journal-title":"Perit. Dial. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.ki.5002014","article-title":"Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands","volume":"71","author":"Liem","year":"2007","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0272-6386(99)70012-0","article-title":"Mortality risks of peritoneal dialysis and hemodialysis","volume":"34","author":"Collins","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000536648","article-title":"Mortality of Peritoneal Dialysis versus Hemodialysis in Older Adults: An Updated Systematic Review and Meta-Analysis","volume":"70","author":"Cheng","year":"2024","journal-title":"Gerontology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s11255-021-03026-y","article-title":"Propensity-matched comparison of mortality between peritoneal dialysis and hemodialysis in patients with type 2 diabetes","volume":"54","author":"Liu","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Liu, L., Pang, J., Xu, J., Liu, L.N., Liao, M.Y., Huang, Q.X., and Li, Y.L. (2023). Impact of initial dialysis modality on the survival of patients with ESRD: A propensity-score-matched study. BMC Nephrol., 24.","DOI":"10.1186\/s12882-023-03312-0"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/ndt\/gfz278","article-title":"Propensity score matched mortality comparisons of peritoneal and in-centre haemodialysis: Systematic review and meta-analysis","volume":"35","author":"Elsayed","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.ajkd.2017.08.028","article-title":"Comparison of Patient Survival Between Hemodialysis and Peritoneal Dialysis Among Patients Eligible for Both Modalities","volume":"71","author":"Wong","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1093\/ndt\/gfq233","article-title":"Risk factors for mortality in diabetic peritoneal dialysis patients","volume":"25","author":"Chung","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gensberger-Reigl, S., Weigel, I., St\u00fctzer, J., Auditore, A., Nikolaus, T., and Pischetsrieder, M. (2022). Degradation and de novo formation of nine major glucose degradation products during storage of peritoneal dialysis fluids. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-08123-1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1523-1755.2003.00705.x","article-title":"Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation?","volume":"63","author":"Zeier","year":"2003","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.0894-0959.2004.17610.x","article-title":"Metabolic consequences of peritoneal dialysis","volume":"17","author":"Burkart","year":"2004","journal-title":"Semin. Dial."},{"key":"ref_23","first-page":"75","article-title":"Continuous glucose monitoring system in 72-h glucose profile assessment in patients with end-stage renal disease on maintenance continuous ambulatory peritoneal dialysis","volume":"16","author":"Skubala","year":"2010","journal-title":"Med. Sci. Monit."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.tem.2021.06.001","article-title":"Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis","volume":"32","author":"Lambie","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.dsx.2019.02.023","article-title":"Insulin resistance is a cardiovascular risk factor in humans","volume":"13","year":"2019","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2337\/dc17-0245","article-title":"The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients with Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey from the European Society of Cardiology","volume":"40","author":"Shahim","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3747\/pdi.2012.00037","article-title":"Insulin resistance as a predictor of cardiovascular disease in patients on peritoneal dialysis","volume":"33","author":"Li","year":"2013","journal-title":"Perit. Dial. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/089686080902902S28","article-title":"Insulin resistance and glucose homeostasis in peritoneal dialysis","volume":"29","author":"Fortes","year":"2009","journal-title":"Perit. Dial. Int."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wang, X.F., Chen, X., Tang, Y., Wu, J.M., Qin, D.L., Yu, L., Yu, C.L., Zhou, X.G., and Wu, A.G. (2022). The Therapeutic Potential of Plant Polysaccharides in Metabolic Diseases. Pharmaceuticals, 15.","DOI":"10.3390\/ph15111329"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1159\/000500979","article-title":"Triglyceride Glucose Index Predicting Cardiovascular Mortality in Chinese Initiating Peritoneal Dialysis: A Cohort Study","volume":"44","author":"Yan","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/089686080902902S29","article-title":"Treatment of metabolic syndrome in peritoneal dialysis patients","volume":"29","author":"Li","year":"2009","journal-title":"Perit. Dial. Int."},{"key":"ref_32","first-page":"e61201","article-title":"Metabolic Syndrome Increases Mortality Risk in Dialysis Patients: A Systematic Review and Meta-Analysis","volume":"16","author":"Sanguankeo","year":"2018","journal-title":"Int. J. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2215\/CJN.08921010","article-title":"Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus","volume":"6","author":"Duong","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wu, H.Y., Hung, K.Y., Huang, T.M., Hu, F.C., Peng, Y.S., Huang, J.W., Lin, S.L., Chen, Y.M., Chu, T.S., and Tsai, T.J. (2012). Safety issues of long-term glucose load in patients on peritoneal dialysis\u2014A 7-year cohort study. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030337"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3747\/pdi.2013.00083","article-title":"High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients","volume":"35","author":"Wen","year":"2015","journal-title":"Perit. Dial. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/archinternmed.2011.2","article-title":"Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: Influence of age at onset, diabetes duration, and established and novel risk factors","volume":"171","author":"Wannamethee","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/1753-0407.12475","article-title":"Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory","volume":"9","author":"Yamagishi","year":"2017","journal-title":"J. Diabetes"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3400\/avd.ra.18-00070","article-title":"Role of Hyperglycemia-Induced Advanced Glycation End Product (AGE) Accumulation in Atherosclerosis","volume":"11","author":"Yamagishi","year":"2018","journal-title":"Ann. Vasc. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2337\/dc10-1087","article-title":"Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12-year follow-up study","volume":"34","author":"Nin","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00125-007-0687-z","article-title":"Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: A population-based 18 year follow-up study","volume":"50","author":"Kilhovd","year":"2007","journal-title":"Diabetologia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.semnephrol.2011.01.006","article-title":"Determinants of peritoneal membrane function over time","volume":"31","author":"Davies","year":"2011","journal-title":"Semin. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0896860819878344","article-title":"Advanced glycation end products are associated with immature angiogenesis and peritoneal dysfunction in patients on peritoneal dialysis","volume":"40","author":"Nakano","year":"2020","journal-title":"Perit. Dial. Int."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Li, J., Xing, H., Lin, W., Yu, H., Yang, B., Jiang, C., Zhang, J., Wu, R., Ding, F., and Pei, M. (2024). Specific gut microbiome and metabolome changes in patients with continuous ambulatory peritoneal dialysis and comparison between patients with different dialysis vintages. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1302352"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Fan, J., Wang, L., Yang, T., Liu, J., Ge, W., Shen, J., and Wang, L. (2024). Comparative analysis of gut microbiota in incident and prevalent peritoneal dialysis patients with peritoneal fibrosis, correlations with peritoneal equilibration test data in the peritoneal fibrosis cohort. Ther. Apher. Dial.","DOI":"10.1111\/1744-9987.14226"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Stepanova, N. (2024). Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102377"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4093\/dmj.2023.0067","article-title":"Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview","volume":"47","author":"Suh","year":"2023","journal-title":"Diabetes Metab. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000499406","article-title":"Counteracting the Metabolic Effects of Glucose Load in Peritoneal Dialysis Patients; an Exercise-Based Approach","volume":"48","author":"Khan","year":"2019","journal-title":"Blood Purif."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00429.2015","article-title":"Advances in high-density lipoprotein physiology: Surprises, overturns, and promises","volume":"310","author":"Constantinou","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-022-00832-x","article-title":"The association between diabetes coexisting with low levels of high-density lipoprotein cholesterol and peritoneal dialysis-related peritonitis","volume":"14","author":"Zhang","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/ndt\/gfz116","article-title":"New-onset glucose disorders in peritoneal dialysis patients: A meta-analysis and systematic review","volume":"35","author":"Xue","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lambie, M., Chess, J., Do, J.Y., Noh, H., Lee, H.B., Kim, Y.L., Summers, A., Williams, P.F., Davison, S., and Dorval, M. (2016). Global Fluid Study Investigators. Peritoneal Dialysate Glucose Load and Systemic Glucose Metabolism in Non-Diabetics: Results from the GLOBAL Fluid Cohort Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155564"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2014). Diagnosis and classification of diabetes mellitus. Diabetes Care, 37, 81\u201390.","DOI":"10.2337\/dc14-S081"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/1744-9987.12800","article-title":"New-Onset Diabetes Mellitus in Peritoneal Dialysis and Hemodialysis Patients: Frequency, Risk Factors, and Prognosis-A Review","volume":"23","author":"Yarragudi","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Chou, C.Y., Liang, C.C., Kuo, H.L., Chang, C.T., Liu, J.H., Lin, H.H., Wang, I.K., Yang, Y.F., and Huang, C.C. (2014). Comparing risk of new onset diabetes mellitus in chronic kidney disease patients receiving peritoneal dialysis and hemodialysis using propensity score matching. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087891"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3747\/pdi.2015.00182","article-title":"Older Age, Higher Body Mass Index and Inflammation Increase the Risk for New-Onset Diabetes and Impaired Glucose Tolerance in Patients on Peritoneal Dialysis","volume":"36","author":"Dong","year":"2016","journal-title":"Perit. Dial. Int."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wu, P.P., Kor, C.T., Hsieh, M.C., and Hsieh, Y.P. (2018). Association between End-Stage Renal Disease and Incident Diabetes Mellitus-A Nationwide Population-Based Cohort Study. J. Clin. Med., 7.","DOI":"10.3390\/jcm7100343"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/j.ajkd.2007.01.018","article-title":"New-onset hyperglycemia in nondiabetic chinese patients started on peritoneal dialysis","volume":"49","author":"Szeto","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2337\/dc12-2148","article-title":"Epidemiology and mortality of new-onset diabetes after dialysis: Taiwan national cohort study","volume":"36","author":"Tien","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1034\/j.1600-6143.2003.00082.x","article-title":"Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients","volume":"3","author":"Woodward","year":"2003","journal-title":"Am. J. Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/ndt\/gfx250","article-title":"Risk of new-onset diabetes in end-stage renal disease patients undergoing dialysis: Analysis from registry data of Taiwan","volume":"33","author":"Wang","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2215\/CJN.03170315","article-title":"Insulin Resistance in Nondiabetic Peritoneal Dialysis Patients: Associations with Body Composition, Peritoneal Transport, and Peritoneal Glucose Absorption","volume":"10","author":"Bernardo","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrneph.2012.13","article-title":"An update on peritoneal dialysis solutions","volume":"8","author":"Lindholm","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Stachowska-Pietka, J., Waniewski, J., Olszowska, A., Garcia-Lopez, E., Yan, J., Yao, Q., Wankowicz, Z., and Lindholm, B. (2024). Can one long peritoneal dwell with icodextrin replace two short dwells with glucose?. Front. Physiol., 15.","DOI":"10.3389\/fphys.2024.1339762"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/ndt\/gfv247","article-title":"Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: Results of a randomized controlled trial (STARCH)","volume":"30","author":"Andreoli","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2012100987","article-title":"IMPENDIA and EDEN Study Groups. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients","volume":"24","author":"Li","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jacl.2014.03.007","article-title":"Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA\/EDEN trials","volume":"8","author":"Sniderman","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.atherosclerosis.2012.08.039","article-title":"Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study","volume":"225","author":"Sniderman","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1159\/000105123","article-title":"Japanese Extraneal Collaborated Study Group. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis","volume":"27","author":"Babazono","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Kanda, E., Ai, M., Iwamoto, A., Okazaki, M., Maeda, Y., Sasaki, S., and Yoshida, M. (2013). Relationship between Icodextrin use and decreased level of small low-density lipoprotein cholesterol fractioned by high-performance gel permeation chromatography. BMC Nephrol., 14.","DOI":"10.1186\/1471-2369-14-234"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2215\/CJN.03650411","article-title":"Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients","volume":"6","author":"Noori","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Chen, Q., Abudukeremu, A., Li, K., Zheng, M., Li, H., Huang, T., Huang, C., Wen, K., Wang, Y., and Zhang, Y. (2024). High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147856"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Huang, Y.F., Zhu, D.J., Chen, X.W., Ouyang, M.Z., and Zhang, W.J. (2015). Biphasic Regulation of Lipid Metabolism: A Meta-Analysis of Icodextrin in Peritoneal Dialysis. Biomed Res. Int., 2015.","DOI":"10.1155\/2015\/208980"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.10041110","article-title":"Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: A randomized controlled trial","volume":"6","author":"Takatori","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wang, I.K., Chan, C.I., Lin, A.H., Yu, T.M., Yen, T.H., Lai, P.C., Li, C.Y., and Sung, F.C. (2024). The impact of icodextrin on the outcomes of incident peritoneal dialysis patients. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0297688"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2991","DOI":"10.1097\/MD.0000000000002991","article-title":"Yonsei Associate Network CHronic Kidney Disease Trial (YACHT) investigators. Effect of Icodextrin Solution on the Preservation of Residual Renal Function in Peritoneal Dialysis Patients: A Randomized Controlled Study","volume":"95","author":"Chang","year":"2016","journal-title":"Medicine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1053\/j.ajkd.2019.10.004","article-title":"Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"75","author":"Goossen","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.02380218","article-title":"Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport","volume":"13","author":"Elphick","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1093\/ckj\/sfad155","article-title":"Impact of peritoneal dialysis strategy on technique and patient survival","volume":"16","author":"Sanchez","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"872","DOI":"10.34067\/KID.0006922021","article-title":"PDOPPS Dialysis Prescription and Fluid Management Working Group. International Icodextrin Use and Association with Peritoneal Membrane Function, Fluid Removal, Patient and Technique Survival","volume":"3","author":"Davies","year":"2022","journal-title":"Kidney360"},{"key":"ref_81","first-page":"CD007554","article-title":"Biocompatible dialysis fluids for peritoneal dialysis","volume":"10","author":"Htay","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3747\/pdi.2012.00279","article-title":"Effect of icodextrin on heart rate variability in diabetic patients on peritoneal dialysis","volume":"34","author":"Orihuela","year":"2014","journal-title":"Perit. Dial. Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/nep.13568","article-title":"Icodextrin is associated with a lower risk of atrial fibrillation in peritoneal dialysis patients","volume":"24","author":"Wang","year":"2019","journal-title":"Nephrology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3747\/pdi.2014.00279","article-title":"ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I\u2014Assessment and Management of Various Cardiovascular Risk Factors","volume":"35","author":"Wang","year":"2015","journal-title":"Perit. Dial. Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11255-010-9716-9","article-title":"Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: One center\u2019s experience and review of the literature","volume":"43","author":"Dousdampanis","year":"2011","journal-title":"Int. Urol. Nephrol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11255-017-1647-2","article-title":"Icodextrin and peritoneal dialysis: Advantages and new applications","volume":"50","author":"Dousdampanis","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1681\/ASN.2024y7zxmncr","article-title":"Double vs. Single Icodextrin Dose in Older Incident Patients on Incremental Continuous Ambulatory Peritoneal Dialysis (CAPD): Results from the DIDo (Double Icodextrin Dose) Study: TH-PO1184","volume":"35","author":"Goffin","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/ki.2015.40","article-title":"Icodextrin skin rash incidence","volume":"87","author":"Biblaki","year":"2015","journal-title":"Kidney Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1681\/ASN.2004090793","article-title":"Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration","volume":"16","author":"Finkelstein","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.ki.5001925","article-title":"New insight of amino acid-based dialysis solutions","volume":"103","author":"Park","year":"2006","journal-title":"Kidney Int. Suppl."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0272-6386(03)00421-9","article-title":"A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD","volume":"42","author":"Li","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/089686089701700312","article-title":"Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis","volume":"17","author":"Misra","year":"1997","journal-title":"Perit. Dial. Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3747\/pdi.2014.00125","article-title":"Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers","volume":"35","author":"Yung","year":"2015","journal-title":"Perit. Dial. Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3109\/0886022X.2010.485287","article-title":"Commencing peritoneal dialysis with 1.1% amino acid solution does not influence biochemical nutritional parameters in incident CAPD patients","volume":"32","author":"Dervisoglu","year":"2010","journal-title":"Ren. Fail."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ndt\/gfad153","article-title":"Associations of neutral pH, low-GDP peritoneal dialysis solutions with patient survival, transfer to haemodialysis and peritonitis","volume":"39","author":"Chen","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.05410514","article-title":"Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis","volume":"10","author":"Yohanna","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ndt\/gfl559","article-title":"Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial","volume":"22","author":"Szeto","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Szeto, C.C., Kwan, B.C., Chow, K.M., Cheng, P.M., Kwong, V.W., Choy, A.S., Law, M.C., Leung, C.B., and Li, P.K. (2015). The Effect of Neutral Peritoneal Dialysis Solution with Low Glucose-Degradation-Product on the Fluid Status and Body Composition--A Randomized Control Trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141425"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3747\/pdi.2014.00291","article-title":"Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions","volume":"36","author":"Cho","year":"2016","journal-title":"Perit. Dial. Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/sdi.12579","article-title":"\u201cBiocompatible\u201d Neutral pH Low-GDP Peritoneal Dialysis Solutions: Much Ado About Nothing?","volume":"30","author":"Misra","year":"2017","journal-title":"Semin. Dial."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40620-020-00804-2","article-title":"The osmo-metabolic approach: A novel and tantalizing glucose-sparing strategy in peritoneal dialysis","volume":"34","author":"Bonomini","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Bonomini, M., Di Liberato, L., Zammit, V., and Arduini, A. (2019). Current Opinion on Usage of L-Carnitine in End-Stage Renal Disease Patients on Peritoneal Dialysis. Molecules, 24.","DOI":"10.3390\/molecules24193449"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"Khunti","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020). KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int., 98, S1\u2013S115.","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0272-6386(04)00951-5","article-title":"Red blood cell survival in chronic renal failure","volume":"44","author":"Ly","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40842-015-0001-9","article-title":"Management of diabetes mellitus in patients with chronic kidney disease","volume":"1","author":"Hahr","year":"2015","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/ki.2008.25","article-title":"Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis","volume":"73","author":"Peacock","year":"2008","journal-title":"Kidney Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3747\/pdi.2014.00011","article-title":"The Effect of Glycated Hemoglobin and Albumin-Corrected Glycated Serum Protein on Mortality in Diabetic Patients Receiving Continuous Peritoneal Dialysis","volume":"35","author":"Peng","year":"2015","journal-title":"Perit. Dial. Int."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Abe, M., Hamano, T., Hoshino, J., Wada, A., Nakai, S., and Masakane, I. (2019). Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-39933-5"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.0894-0959.2004.17603.x","article-title":"Serum albumin: Relationship to inflammation and nutrition","volume":"17","author":"Don","year":"2004","journal-title":"Semin. Dial."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/0004563214568162","article-title":"Serum albumin-adjusted glycated albumin is a better indicator of glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis","volume":"52","author":"Fukami","year":"2015","journal-title":"Ann. Clin. Biochem."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Ling, J., Ng, J.K.C., Chan, J.C.N., and Chow, E. (2022). Use of Continuous Glucose Monitoring in the Assessment and Management of Patients with Diabetes and Chronic Kidney Disease. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.869899"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1681\/ASN.2006070772","article-title":"Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection","volume":"18","author":"Inaba","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Kobayashi, H., Abe, M., Yoshida, Y., Suzuki, H., Maruyama, N., and Okada, K. (2016). Glycated Albumin versus Glycated Hemoglobin as a Glycemic Indicator in Diabetic Patients on Peritoneal Dialysis. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050619"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0004563219873688","article-title":"Superiority of glycated albumin over glycated haemoglobin as indicator of glycaemic control and predictor of all-cause mortality in patients with type 2 diabetes mellitus receiving peritoneal dialysis","volume":"56","author":"Miyabe","year":"2019","journal-title":"Ann. Clin. Biochem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/ndt\/gfac297","article-title":"Glycated albumin to glycated hemoglobin ratio and mortality in diabetic patients on dialysis: A new association","volume":"38","author":"Hoshino","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-0042-124577","article-title":"Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis","volume":"125","author":"Rasche","year":"2017","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000519493","article-title":"Hemoglobin A1c and Fructosamine Evaluated in Patients with Type 2 Diabetes Receiving Peritoneal Dialysis Using Long-Term Continuous Glucose Monitoring","volume":"146","author":"Bomholt","year":"2022","journal-title":"Nephron"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Lee, S.Y., Chen, Y.C., Tsai, I.C., Yen, C.J., Chueh, S.N., Chuang, H.F., Wu, H.Y., Chiang, C.K., Cheng, H.T., and Hung, K.Y. (2013). Glycosylated hemoglobin and albumin-corrected fructosamine are good indicators for glycemic control in peritoneal dialysis patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057762"},{"key":"ref_120","first-page":"e33549","article-title":"An Assessment of the Utility of Serum Fructosamine in the Diagnosis and Monitoring of Diabetes Mellitus","volume":"15","author":"John","year":"2023","journal-title":"Cureus"},{"key":"ref_121","first-page":"34","article-title":"A Comparison Study of Glucose Fluctuation During Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis","volume":"31","author":"Okada","year":"2015","journal-title":"Adv. Perit. Dial."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International Consensus on Use of Continuous Glucose Monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000525676","article-title":"Can the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis?","volume":"147","author":"Bomholt","year":"2023","journal-title":"Nephron"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000363417","article-title":"Practical considerations when prescribing icodextrin: A narrative review","volume":"39","author":"Silver","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/dme.12988","article-title":"Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: Poor correlation with HbA1c and high incidence of hypoglycaemia","volume":"33","author":"Oei","year":"2016","journal-title":"Diabet. Med."},{"key":"ref_126","first-page":"213","article-title":"Assessing 24-h blood glucose patterns in diabetic paitents treated by peritoneal dialysis","volume":"20","author":"Schwing","year":"2004","journal-title":"Adv. Perit. Dial."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000439242","article-title":"Continuous Glucose monitoring in patients with diabetes mellitus on peritoneal dialysis: Correlation with glycated hemoglobin and detection of high incidence of unaware hypoglycemia","volume":"41","author":"Qayyum","year":"2016","journal-title":"Blood Purif."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1046\/j.1523-1755.2003.00209.x","article-title":"Glycemic Control in Diabetic Capd Patients Assessed by Continuous Glucose Monitoring System (Cgms)","volume":"64","author":"Marshall","year":"2003","journal-title":"Kidney Int."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2337\/dc22-2348","article-title":"Evaluation of a Fourth-Generation Subcutaneous Real-Time Continuous Glucose Monitor (CGM) in Individuals with Diabetes on Peritoneal Dialysis","volume":"46","author":"Ng","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/dia.2023.0349","article-title":"Impact of Body Composition and Anemia on Accuracy of a Real-Time Continuous Glucose Monitor in Diabetes Patients on Continuous Ambulatory Peritoneal Dialysis","volume":"26","author":"Ling","year":"2024","journal-title":"Diabetes Technol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2021.7444","article-title":"Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin: A Randomized Clinical Trial","volume":"325","author":"Martens","year":"2021","journal-title":"JAMA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000510613","article-title":"The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis","volume":"145","author":"Bomholt","year":"2021","journal-title":"Nephron"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.ajkd.2020.03.008","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2021.05.023","article-title":"Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022","volume":"79","author":"Hahr","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2021.09.010","article-title":"KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD","volume":"79","author":"Mottl","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s40262-018-0649-2","article-title":"Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment","volume":"57","author":"Granhall","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2009.03536.x","article-title":"Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide","volume":"68","author":"Jacobsen","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ekir.2023.01.040","article-title":"Narrative Review of Glycemic Management in People with Diabetes on Peritoneal Dialysis","volume":"8","author":"Wijewickrama","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Lin, M.H., Yang, H.Y., Yen, C.L., Wu, C.Y., Jenq, C.C., Kuo, G., Peng, W.S., Liu, J.R., Tian, Y.C., and Yang, C.W. (2020). Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006\u20132016. J. Clin. Med., 9.","DOI":"10.20944\/preprints202010.0021.v1"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e14769","DOI":"10.1111\/dme.14769","article-title":"Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease","volume":"39","author":"Karalliedde","year":"2022","journal-title":"Diabet. Med."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Balzer, M.S., Rong, S., Nordlohne, J., Zemtsovski, J.D., Schmidt, S., Stapel, B., Bartosova, M., von Vietinghoff, S., Haller, H., and Schmitt, C.P. (2020). SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate. Biomolecules, 10.","DOI":"10.1101\/2020.11.04.366724"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000520894","article-title":"Peritoneal Expression of SGLT-2, GLUT1, and GLUT3 in Peritoneal Dialysis Patients","volume":"47","author":"Schricker","year":"2022","journal-title":"Kidney Blood Press. Res."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Wang, J., Lv, X., A-Ni-Wan, A.S., Tian, S.S., Wang, J.M., Liu, H.Y., Fan, X.G., Zhou, S.J., and Yu, P. (2023). Canagliflozin alleviates high glu-cose-induced peritoneal fibrosis via HIF-1\u03b1 inhibition. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1152611"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Lai, J.W., Wang, C.C.N., and Chou, C.Y. (2024). SGLT-2 inhibitors in chronic peritoneal dialysis patients: A follow-up study. BMC Nephrol., 25.","DOI":"10.1186\/s12882-024-03683-y"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Moral Berrio, E., De La Flor, J.C., Arambarri Segura, M., Rodr\u00edguez-Doy\u00e1g\u00fcez, P., Mart\u00ednez Calero, A., Zamora, R., Cieza-Terrones, M., Yuste-Lozano, C., S\u00e1nchez de la Nieta Garc\u00eda, M.D., and Nieto Iglesias, J. (2024). Effects of Sodium\u2013Glucose Cotransporter 2 Inhibitors in Diabetic and Non-Diabetic Patients with Advanced Chronic Kidney Disease in Peritoneal Dialysis on Residual Kidney Function: In Real-World Data. Medicina, 60.","DOI":"10.3390\/medicina60081198"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26502\/anu.2644-2833047","article-title":"The Use of SGLT2 Inhibitors in Peritoneal Dialysis Patients: A Shade of Light on Dapagliflozin","volume":"5","author":"Alhwiesh","year":"2022","journal-title":"Arch. Nephrol. Urol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/phar.2659","article-title":"Systematic literature review of insulin dose adjustments when initiating hemodialysis or peritoneal dialysis","volume":"42","author":"Blaine","year":"2022","journal-title":"Pharmacotherapy"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/ndt\/gfl834","article-title":"Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis","volume":"22","author":"Szeto","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1932296817730376","article-title":"Impact of a basal-bolus insulin regimen on metabolic control and risk of hypoglycemia in patients with diabetes undergoing peritoneal dialysis","volume":"12","author":"Vallejo","year":"2018","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diacare.18.4.517","article-title":"Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms","volume":"18","author":"Clarke","year":"1995","journal-title":"Diabetes Care"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/5\/798\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:32Z","timestamp":1760031272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/5\/798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":151,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["life15050798"],"URL":"https:\/\/doi.org\/10.3390\/life15050798","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]}}}